Clinical Trial Update: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing a proposed rituximab biosimilar (DRL_RI) to MabThera in follicular lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• DRL_RI (rituximab biosimilar)
• MabThera (rituximab)

Snippet

Sponsor: Dr. Reddy's Laboratories Limited | Conditions: Follicular Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2024-01-22